PRIVATE ITEM
Digitization of this item is currently in progress.
Assessing the Efficacy of Eufortyn - A Terclatrated CoQ10 and Creatine Combination Therapy on the Aging Rat Model
ALL VOLUMES CITATION PAGE IMAGE ZOOMABLE
Full Citation
STANDARD VIEW MARC VIEW
Permanent Link: http://ufdc.ufl.edu/UF00091523/00578
 Material Information
Title: Assessing the Efficacy of Eufortyn - A Terclatrated CoQ10 and Creatine Combination Therapy on the Aging Rat Model
Series Title: Journal of Undergraduate Research
Physical Description: Serial
Language: English
Creator: Vorobyeva, Darya
Leeuwenburgh, Christiaan ( Mentor )
Publisher: University of Florida
Place of Publication: Gainesville, Fla.
Publication Date: 2009
 Notes
Abstract: With the progression of age, the organism enters a highly oxidized state resulting from impaired mitochondrial function. As the susceptibility to reactive oxygen species heightens, a decline of both size and number of skeletal muscle fibers manifests in chronic fatigue syndrome known as sarcopenia in the elderly. Consumption of antioxidant as part of a diet may help regulate oxidative damage by reducing the rampant activity of reactive oxygen species in the cell, yet the poor bioavailability of most commercial supplements limit the capacity of the antioxidant to quench free-radicals. Eufortyn is a terclatrated formulation of Coenzyme Q10, creatine, and ginseng extract that retains the integrity of the antioxidant moiety, while allowing maximal absorption into the intestinal mucosa. A Eufortyn pellet was fed orally to 19 and 27-month old Fischer 344 x BNF1 rats for six weeks. Grip strength improved (12%) in 19-mos, but not in 27-mos old rats. Water maze analysis exhibited sharpened cognitive performance in Eufortyn-treated old-age rats compared to their age-match peers. Significant advancement in mitochondrial calcium retention capacity (66% in 19-mos and 19% in 27-mos), diminished non-heme iron levels (54% in 27-mos), and suppressed nucleic acid oxidation (31% in 19-mos and 24% in 27-mos) were observed in skeletal muscle in Eufortyn-treated cohorts. These findings indicate that treatment is more effective in the middle-aged animals in comparison to the 27-month old rats suggesting that intervention with Eufortyn needs to be initiated at an earlier age than 27-month old to see optimal effects.
 Record Information
Source Institution: University of Florida
Holding Location: University of Florida
Rights Management: All rights reserved by the source institution and holding location.
System ID: UF00091523:00578

University of Florida Home Page
© 2004 - 2011 University of Florida George A. Smathers Libraries.
All rights reserved.

Acceptable Use, Copyright, and Disclaimer Statement
Last updated May 24, 2011 - Version 2.9.11 - mvs